Xiamen University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Xiamen China (1921)

Organization Overview

First Clinical Trial
2007
NCT01014845
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Clinical Trial Center of Xiamen Cardiovascular Hospital | First affiliated Hospital of Xiamen University | Fuzhou General Hospital, Xiamen Univ | National Institute of Diagnostics and Vaccine Development in infectious disease | National Institute of Diagnostics and Vaccine Development in infectious disease, Xiamen University | Southeast Hospital affiliated to Xiamen University | The First Affiliated Hospital of Xiamen University | The First Affiliated Hospital of Xiamen University, China | The First Affiliated of Xiamen University | The first afilliated hospital of Xiamen university | The First Aiffiliated hosptical of xiamen University | Xiamen Cardiovascular Hospital, Xiamen University | Xiamen Chang gung hospital | Xiamen Children's Hospital | Xiamen Children's Hospital, Fujian of China | Xiamen Eye Center Affiliated to Xiamen University | Xiamen Eye Center of Xiamen University | Xiamen Hospital of Traditional Chinese Medicine | Xiamen traditional Chinese medicine hospital | Xiamen University | Xiamen University Malaysia | Xiamen University Zhongshan Hospital | Xiang'an Hospital of Xiamen University | Zhang Ying Qian | ZhiYong Peng | Zhongnan Hospital | Zhongshan boai Hospital | Zhongshan Hospital affiliated to Fu Dan University | Zhongshan Hospital Affiliated to Xiamen University | Zhongshan Hospital Of Traditional Chinese Medicine | Zhongshan Hospital, Shanghai | Zhongshan Hospital, Shanghai, China | Zhongshan Hospital Xiamen University | Zhongshan Ophthalmic center, Sun Yat-sen University | Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China | Zhongshan People's Hospital | Zhongshan People's Hospital, Guangdong, China | Zhongshan University Affliated Cancer Hospital

Active Ingredients

Drugs in Phase 4 Trials (38)

azelastine (astelin) (1 trial)

basiliximab (Simulect) (2 trials)

cinacalcet (sensipar) (1 trial)

cyclosporine (sandimmune) (1 trial)

dapagliflozin (farxiga) (2 trials)

deng zhan sheng mai (1 trial)

dexamethasone (2 trials)

dexmedetomidine (precedex) (2 trials)

eltrombopag (promacta) (1 trial)

empagliflozin (jardiance) (1 trial)

esketamine (spravato) (1 trial)

exenatide (byetta) (1 trial)

fluticasone (cutivate) (1 trial)

fruquintinib (Fruzaqla) (3 trials)

hepatitis e vaccine (5 trials)

human fecal microbiota (Reybota) (7 trials)

immune globulin (human) (Gamastan) (1 trial)

insulin glargine (toujeo) (1 trial)

insulin lispro (humalog) (2 trials)

interferon alpha-2b (Intron-A) (1 trial)

levetiracetam (keppra) (1 trial)

levothyroxine (Synthroid) (1 trial)

liothyronine (cytomel) (1 trial)

liraglutide (victoza) (1 trial)

mycophenolate (CellCept) (2 trials)

naltrexone (revia) (1 trial)

nicorandil (1 trial)

phenobarbital (Luminal) (1 trial)

prednisone (meticorten) (5 trials)

rc48-adc (2 trials)

rifampin (1 trial)

rituximab (rituxan) (2 trials)

sargramostim (leukine) (3 trials)

sodium chloride (2 trials)

somatropin (protropin) (1 trial)

thrombopoietin (2 trials)

vildagliptin (1 trial)

xingnaojing (1 trial)

Drugs in Phase 3 Trials (49)

131i-lipiodol (Lipiodol) (2 trials)

amlodipine (norvasc) (1 trial)

azacitidine (vidaza) (4 trials)

betaxolol (kerlone) (1 trial)

bevacizumab (avastin) (2 trials)

borneol (1 trial)

camrelizumab (9 trials)

capecitabine (xeloda) (2 trials)

carboplatin (paraplatin) (6 trials)

cetuximab (erbitux) (1 trial)

cisplatin (platinol) (16 trials)

docetaxel (taxotere) (7 trials)

doxycycline (vibramycin) (2 trials)

enzalutamide (xtandi) (1 trial)

epirubicin (ellence) (1 trial)

fluorouracil (efudex) (5 trials)

gelatin (1 trial)

gemcitabine (gemzar) (3 trials)

Homoharringtonine (1 trial)

hpv 16/18 vaccine (Cervarix) (3 trials)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (5 trials)

hydrochlorothiazide (esidrix) (1 trial)

irinotecan (Camptosar) (2 trials)

iron succinate (1 trial)

lenvatinib (lenvima) (1 trial)

levobetaxolol (betaxon) (1 trial)

linaclotide (linzess) (1 trial)

losartan (cozaar) (1 trial)

lotilaner (xdemvy) (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

methimazole (tapazole) (1 trial)

methylprednisolone (medrol) (1 trial)

nedaplatin (1 trial)

nimotuzumab (1 trial)

nitric oxide (inomax) (1 trial)

paclitaxel (taxol) (9 trials)

pirarubicin (1 trial)

polyethylene glycol (1 trial)

pomalidomide (pomalyst) (1 trial)

potassium sulfate (1 trial)

rifaximin (xifaxan) (1 trial)

ringer's lactate (2 trials)

shengxuening (1 trial)

sintilimab (4 trials)

sodium sulfate (1 trial)

tanfanercept (1 trial)

toripalimab (LOQTORZ) (5 trials)

venetoclax (venclexta) (3 trials)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (49)

ad5-ncov (3 trials)

ak104 (1 trial)

allogeneic cord blood (1 trial)

amino acids (Freamine) (1 trial)

anlotinib (3 trials)

autologous mesenchymal stem cells (2 trials)

bone autograft (1 trial)

c-117 (1 trial)

chidamide (6 trials)

cyclophosphamide (cytoxan) (3 trials)

cytarabine (cytosar-u) (1 trial)

d-0316 (1 trial)

dactinomycin (cosmegen) (2 trials)

doxorubicin (Doxil) (3 trials)

duvelisib (copiktra) (1 trial)

envafolimab (1 trial)

epoetin (Epogen) (1 trial)

erlotinib (tarceva) (1 trial)

etoposide (vepesid) (2 trials)

gimeracil (2 trials)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (2 trials)

icotinib (Conmana) (1 trial)

indocyanine green (ic-green) (1 trial)

lapatinib (tykerb) (6 trials)

lenalidomide (revlimid) (2 trials)

leucovorin (1 trial)

metformin (glucophage) (1 trial)

mitoxantrone (novantrone) (1 trial)

obinutuzumab (gazyva) (1 trial)

oteracil (2 trials)

oxaliplatin (eloxatin) (3 trials)

pemetrexed (alimta) (1 trial)

pemigatinib (Pemazyre) (1 trial)

pyrotinib (1 trial)

Raltitrexed (Tomudex) (1 trial)

recombinant human papillomavirus virus type 6/11 bivalent vaccine (1 trial)

shr-1316 (1 trial)

surufatinib (1 trial)

svf-derived mesenchymal stem cells (1 trial)

tegafur (2 trials)

thymalfasin (zadaxin) (1 trial)

tirelizumab (1 trial)

tislelizumab (1 trial)

tretinoin (Retin-A) (1 trial)

umbilical cord mesenchymal stem cells (3 trials)

vincristine (oncovin) (2 trials)

vindesine (Eldisine) (1 trial)

vitamin c (3 trials)

yy-20394 (1 trial)

Drugs in Phase 1 Trials (10)

177lu-dota-fapi (2 trials)

177lu-lnc1010 1 (1 trial)

68ga-dota-fapi (2 trials)

68ga-fapi (2 trials)

abiraterone (zytiga) (1 trial)

aluminum (1 trial)

bortezomib (velcade) (1 trial)

bs-006 (1 trial)

Filgrastim (neupogen) (1 trial)

umbilical cord blood derived mak immune cells (1 trial)

Drugs in Other Trials (20)

artemisia (1 trial)

bivalent bnt162b2 (Comirnaty) (1 trial)

colchicine (colbenemid) (1 trial)

covid-19 mrna vaccine (1 trial)

desflurane (suprane) (1 trial)

gardenia jasminoides ellis (1 trial)

longshengzhi (1 trial)

midazolam (versed) (1 trial)

paeoniae radix (1 trial)

pentixafor (1 trial)

polidocanol (asclera) (1 trial)

remimazolam (Byfavo) (1 trial)

rhizoma atractylodis macrocephalae (1 trial)

ropivacaine (naropin) (1 trial)

rubia cordifolia (1 trial)

salvia (1 trial)

sars-cov-2 mrna vaccine (1 trial)

sheng jing (1 trial)

sieyesbeckiaorientalis (1 trial)

thalidomide (Thalomid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Adenocarcinoma (Phase 2)

Adenoviridae Infections (Phase 2)

Albuminuria (Phase 4)

Angina, Unstable (Phase 4)

beta-Thalassemia (Phase 4)

Brain Diseases (Phase 2)

Breast Neoplasms (Phase 3)

Bronchopulmonary Dysplasia (Phase 3)

Burns (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma in Situ (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Cerebral Infarction (Phase 4)

Cervical Intraepithelial Neoplasia (Phase 3)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Constipation (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 4)

Diarrhea (Phase 3)

Dry Eye Syndromes (Phase 3)

Dwarfism, Pituitary (Phase 4)

Endocrine System Diseases (Phase 4)

Esophageal Squamous Cell Carcinoma (Phase 3)

Eye Burns (Phase 3)

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Graft vs Host Disease (Phase 4)

Graves Ophthalmopathy (Phase 3)

Hematologic Diseases (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis E (Phase 4)

Hepatoblastoma (Phase 4)

Hyperglycemia (Phase 4)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Hypertension (Phase 3)

Infections (Phase 3)

Inflammatory Bowel Diseases (Phase 1)

Intestinal Diseases (Phase 1)

Intracranial Arteriosclerosis (Phase 2)

Intracranial Embolism (Phase 2)

Intracranial Thrombosis (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Ischemia (Phase 4)

Keratoconjunctivitis Sicca (Phase 3)

Kidney Diseases (Phase 4)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Malnutrition (Phase 3)

Nasopharyngeal Carcinoma (Phase 3)

Nasopharyngeal Neoplasms (Phase 3)

Neointima (Phase 4)

Neoplasm Metastasis (Phase 4)

Neoplasms (Phase 3)

Neuroblastoma (Phase 4)

Ocular Hypertension (Phase 3)

Ovarian Neoplasms (Phase 2)

Overweight (Phase 4)

Peritoneal Neoplasms (Phase 3)

Pneumonia (Phase 2)

Pneumonia, Ventilator-Associated (Phase 2)

Pneumonia, Viral (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Premature Birth (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 4)

Retinoblastoma (Phase 4)

Seizures (Phase 4)

Sepsis (Phase 3)

Stomach Neoplasms (Phase 2)

Stroke (Phase 4)

Syndrome (Phase 3)

Thalassemia (Phase 4)

Thrombocytopenia (Phase 4)

Thrombosis (Phase 3)

Toxemia (Phase 3)

Ulcer (Phase 4)

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 160
  • # of Trial APIs: 166